BAUSSS biomarker further validated as a key risk staging tool for patients with primary melanoma
J Eur Acad Dermatol Venereol
.
2024 Sep;38(9):e779-e781.
doi: 10.1111/jdv.19889.
Epub 2024 Feb 20.
Authors
Anthony J Dixon
1
,
Athanassios Kyrgidis
2
,
Michael Sladden
3
,
Alexander Nirenberg
1
,
Howard K Steinman
4
,
Harvey Smith
5
,
Christopher B Zachary
6
,
Stuart Anderson
7
,
Ulrike Leiter-Stöppke
8
,
Caterina Longo
9
10
,
Zoe Apalla
2
Affiliations
1
Australasian College of Cutaneous Oncology, Docklands, Victoria, Australia.
2
Aristotle University of Thessaloniki, Thessaloniki, Greece.
3
University of Tasmania, Launceston, Tasmania, Australia.
4
Campbell University, Buies Creek, North Carolina, USA.
5
Oxford Dermatology, Mt Hawthorn, Perth, Western Australia, Australia.
6
Department of Dermatology, University of California Irvine, Irvine, California, USA.
7
Maffra Medical Group, Maffra, Victoria, Australia.
8
Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.
9
Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
10
Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Skin Cancer Center, Reggio Emilia, Italy.
PMID:
38375764
DOI:
10.1111/jdv.19889
No abstract available
Publication types
Letter
Validation Study
MeSH terms
Biomarkers, Tumor
Female
Humans
Male
Melanoma* / diagnosis
Melanoma* / pathology
Middle Aged
Neoplasm Staging*
Risk Assessment / methods
Skin Neoplasms* / diagnosis
Skin Neoplasms* / pathology
Substances
Biomarkers, Tumor